Strengths And Weaknesses Of Willingham's Theory, Independent Fundamental Baptist Rules, Duckling Died While Hatching, New Idea Manure Spreader Parts, High Damp Readings On Homebuyer Report Should I Still Buy, Articles N

Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Thank you for taking the time to confirm your preferences. 2022 CBS Interactive Inc. All Rights Reserved. Novavax is not responsible for the privacy policy of any third-party websites. FDA authorization of Novavaxs vaccines comes as the U.S. is preparing to updated Covid shots to target the omicron BA.4 and BA.5 variants to increase protection The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes. Thank you for taking the time to confirm your preferences. Get this delivered to your inbox, and more info about our products and services. "I am excited to be joining Novavax at this important time in the company's history," said John C. Jacobs, President and Chief Executive Officer, Novavax. Avoid combinations; the risk of the interaction outweighs the benefit. WebThe recipients health condition or recommendations for vaccination may change from one visit to the next. CBS News reporter covering public health and the pandemic. Similar to the Pfizer-BioNTech and Moderna COVID-19 vaccines, the Novavax vaccine is administered in two doses, per the FDA. GAITHERSBURG, Md., Feb. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global companyadvancing protein-based vaccines with its novel Matrix-M adjuvant, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2022. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Alastair Grant, Associated Press. The effectiveness of Covid vaccines against mild illness has slipped substantially as the virus as evolved, though they still generally protect against severe disease. The COVID ", "Over the past few weeks, the management team and I have identified three near-term priorities that we believe are essential to our success this year and beyond: 1) to deliver a competitive product for the upcoming 2023 fall vaccination season; 2) to reduce our rate of spend, manage our cash flow, and evolve our scale and structure; and 3) to leverage our technology platform, our capabilities and our portfolio of assets to drive additional value beyond Nuvaxovid alone.